Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Jefferies Group decreased their Q2 2016 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued on Tuesday, according to Zacks Investment Research. Jefferies Group analyst E. Yang now expects that the brokerage will earn ($0.28) per share for the quarter, down from their […]
